TORONTO, Sept. 7 /PRNewswire-FirstCall/ - ARIUS Research Inc., , a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that it will deliver poster presentations at two scientific conferences reporting preclinical data for two of its anti-cancer antibody drug candidates.
At the 2007 Breast Cancer Symposium in San Francisco on September 7-8, Arius will report recent results of its antibody candidate that targets CD44, an antigen implicated as a cancer stem cell marker. The poster outlines recent results for this antibody which demonstrate that it is a potent therapeutic in breast cancer models both in vivo and in vitro. The poster also highlights the prevalence of the epitope targeted by Arius’ antibody in breast cancer patients.
The poster presentation is entitled “Development of a potent therapeutic monoclonal antibody targeting CD44 in breast cancer” and will be presented at General Poster Session D, 11:45-12:45 pm on Saturday, September 8th at the San Francisco Marriott.
At the XIth European Meeting on Complement in Human Disease held in Cardiff, Wales on September 8-11, Arius will report results demonstrating that its monoclonal antibody targeting CD59, a cell surface molecule involved in regulating cell lysis mediated by the complement system, is a potent therapeutic in various in vivo cancer models. Arius has demonstrated that its antibody is highly potent at low doses and its efficacy in certain models compares favorably to Taxotere.
The poster presentation is entitled “AR36A36.11.1, a monoclonal antibody targeting CD59, enhances complement activity and exhibits potent in vivo efficacy in multiple human cancer models” and will be presented at Poster Session 1: Inflammatory diseases, therapeutics and diagnostics, 4:00-6:00 pm on Sunday, September 9th at Cardiff City Hall, Cathay’s Park.
About ARIUS
ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 400 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol “ARI”. For further information, visit www.ariusresearch.com
Forward-Looking Statements
Certain statements in this news release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS’ Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
ARIUS Research Inc.
CONTACT: Warren Whitehead, C.M.A., Chief Financial Officer, ARIUS ResearchInc., (416) 862-2323 ext. 214, wwhitehead@ariusresearch.com,contact@ariusresearch.com; James Smith, Investor Relations, (416) 815-0700ext. 229, jsmith@equicomgroup.com
